000 02105nam  2200433zi 4500
0019.928221
003CaOODSP
00520240725133519
006m     o  d f      
007cr cn|||||||||
008231005t20232023onca    ob   f000 0 eng d
020 |a9780660682013
040 |aCaOODSP|beng|erda|cCaOODSP
043 |an-cn---
0861 |aH164-327/2023E-2-PDF
24500|aGuidance on nitrosamine impurities in medications.
264 1|aOttawa, ON : |bHealth Canada = Santé Canada, |c2023.
264 4|c©2023
300 |a1 online resource (iii, 64 pages) : |billustrations
336 |atext|btxt|2rdacontent
337 |acomputer|bc|2rdamedia
338 |aonline resource|bcr|2rdacarrier
500 |aCover title.
500 |a"Date Adopted: October 20, 2023. Effective Date: October 20, 2023."
500 |aIssued also in French under title: Lignes directrices sur les impuretés de nitrosamine dans les médicaments.
504 |aIncludes bibliographical references.
520 |a"Evaluating and managing the risks of N-nitrosamine impurities in human pharmaceutical, biological and radiopharmaceutical products"--Cover.
650 0|aNitrosoamines|xRisk assessment|zCanada.
650 0|aDrugs|xRisk assessment|zCanada.
650 0|aBiologicals|xRisk assessment|zCanada.
650 0|aRadiopharmaceuticals|xRisk assessment|zCanada.
650 0|aPharmaceutical policy|zCanada.
7101 |aCanada. |bHealth Canada, |eissuing body.
77508|tLignes directrices sur les impuretés de nitrosamine dans les médicaments.|w(CaOODSP)9.928223
794 |tGuidance on nitrosamine impurities in medications.|b(March 2024)|w(CaOODSP)9.933796
795 |tGuidance on nitrosamine impurities in medications.|b(July 2023)|w9.924897
85640|qPDF|s1.18 MB|uhttps://publications.gc.ca/collections/collection_2024/sc-hc/H164-327-2023-eng-2.pdf
8564 |qHTML|sN/A|uhttps://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/information-health-product/drugs/nitrosamine-impurities/medications-guidance.html